Management of Metastatic Castration-Naïve Prostate Cancer

  • Axel HeidenreichEmail author
  • Maximilian Schmautz
  • Konstantin Richter
  • David Pfister
Living reference work entry


About 10% of newly diagnosed prostate cancer patients harbor systemic metastases requiring local and systemic therapy. In well-selected patients, cytoreductive radical prostatectomy or local radiation therapy to the primary exerts a beneficial effect on failure-free and overall survival. Systemic therapy might consist of ADT alone, ADT in combination with docetaxel, and ADT in combination with abiraterone and prednisone. CHAARTED and STAMPEDE have demonstrated a significant survival benefit for the combination of ADT plus docetaxel. This survival benefit was only demonstrated for patients with high-risk disease in the CHAARTED trials, whereas no stratification was performed in STAMPEDE. PSA nadir ≤0.2 ng/ml achieved 7 months after ADT is a significant prognostic marker associated with a significant survival benefit as compared to a PSA nadir >0.2 ng/ml. Also, a significant survival benefit was observed for the combination of ADT plus abiraterone acetate and prednisone in the LATITUDE trial for high-risk patients and in the STAMPEDE trial for the total cohort of patients. For daily routine, both combination therapies exert a significant and clinically relevant survival benefit. It is unclear which sequence is to be used, and it appears to be most appropriate to select the treatment option based on the comorbidities of the patient.


Prostate cancer Bone metastases Androgen deprivation LHRH analogues LHRH antagonists Docetaxel Abiraterone acetate 


  1. Cifuentes FF, et al. Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer. Oncol Rep. 2015;34:2837–44.CrossRefGoogle Scholar
  2. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER- based study. Eur Urol. 2014;65(6):1058–66.CrossRefGoogle Scholar
  3. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.CrossRefGoogle Scholar
  4. Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, Karakiewicz P, Guazzoni G, Montorsi F, Briganti A, Menon M, Abdollah F. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;6:3–6.CrossRefGoogle Scholar
  5. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589–604.CrossRefGoogle Scholar
  6. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73(2):178–211.CrossRefGoogle Scholar
  7. Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66:602–3.CrossRefGoogle Scholar
  8. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.CrossRefGoogle Scholar
  9. Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B, Walz J, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Oudard S. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model. Eur Urol. 2015;68(2):196–204.CrossRefGoogle Scholar
  10. Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ, ECOG-ACRIN 3805 Investigators. Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. J Clin Oncol. 2018;36(4):376–82.CrossRefGoogle Scholar
  11. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration- resistant prostate cancer. Eur Urol. 2014;65(2):467–79.CrossRefGoogle Scholar
  12. Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case- control study. J Urol. 2015;193(3):832–8.CrossRefGoogle Scholar
  13. Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmüller B, Gandaglia G, Briganti A, Karnes RJ. Radical cytoreductive prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol. 2018; (in press).Google Scholar
  14. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D, Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984–90.CrossRefGoogle Scholar
  15. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 Patients in the control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–38.CrossRefGoogle Scholar
  16. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O’Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK, STAMPEDE Investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.CrossRefGoogle Scholar
  17. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O’Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR, STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.CrossRefGoogle Scholar
  18. Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI. Local therapy improves survival in metastatic prostate cancer. Eur Urol. 2017;72(1):118–24.CrossRefGoogle Scholar
  19. Morris MJ, Rumble RB, Basch E, Hotte SJ, Loblaw A, Rathkopf D, Celano P, Bangs R, Milowsky MI. Optimizing anticancer therapy in metastatic non-castrate prostate cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;2:JCO2018780619. [Epub ahead of print].CrossRefGoogle Scholar
  20. Mottet N, De Santis M, Briers E, Bourke L, Gillessen S, Grummet JP, Lam TB, van der Poel HG, Rouvière O, van den Bergh RCN, Cornford P. Updated guidelines for metastatic hormone-sensitive prostate cancer: abiraterone acetate combined with castration is another standard. Eur Urol. 2017; [Epub ahead of print].CrossRefGoogle Scholar
  21. Poelaert F, Verbaeys C, Rappe B, Kimpe B, Billiet I, Plancke H, Decaestecker K, Fonteyne V, Buelens S, Lumen N. Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective LoMP trial. Urology. 2017; pii: S0090-4295(17)30372-2. [Epub ahead of print].CrossRefGoogle Scholar
  22. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34:2835–42.CrossRefGoogle Scholar
  23. Rydzewska LHM, Burdett S, Vale CL, Clarke N, Fizazi K, Kheoh K, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran NP, Tierney JT, the STOPCaP Abiraterone Collaborators. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88–101.CrossRefGoogle Scholar
  24. Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, et al. A Multi- institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol. 2015;69:788–94.CrossRefGoogle Scholar
  25. Steuber T, Berg KD, Røder MA, Brasso K, Iversen P, Huland H, Tiebel A, Schlomm T, Haese A, Salomon G, Budäus L, Tilki D, Heinzer H, Graefen M, Mandel P. Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus. 2017; pii: S2405-4569(17)30171-2.Google Scholar
  26. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8): 737–46.CrossRefGoogle Scholar
  27. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;29(18): 2574–81.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Axel Heidenreich
    • 1
    Email author
  • Maximilian Schmautz
    • 1
  • Konstantin Richter
    • 1
  • David Pfister
    • 1
  1. 1.Department of Urology, Urologic Oncology, Robot-assisted and Specialized Urologic SurgeryUniversity Hospital CologneKölnGermany

Section editors and affiliations

  • Thomas Steuber
    • 1
  1. 1.Martini-Klinik am UKE GmbHHamburgGermany

Personalised recommendations